GSK’s ADC prospects brighten further with Hansoh’s second Phase III triumph

Phase 3positiveris-rezPositive

AI Analysis

Summary

GSK's ADC candidate ris-rez achieved positive results in a second Phase III trial in collaboration with Hansoh, strengthening GSK's oncology pipeline prospects for future growth.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Second Phase III trial positive results for ADC ris-rez

Importance:7/10

Sentiment:

0.75

ADConcologyPhase 3positive resultsGSKHansoh

Related Companies

$GSK $HNPHY

Read the original article

Published by Clinical Trials Arena on July 29, 2026 9:38 AM

Read Original